Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison

American Journal of Kidney Diseases

Volumn 37, Issue 3, 2001, Pages 532-543

  Maung, Hla M ^a,b,c,d,e,f   Elangovan, Loganathan ^a,b,c,d,e,f   Frazão, João M ^a,b,c,d,e,f   Bower, John D ^a,b,c,d,e,f   Kelley, Bobby J ^a,b,c,d,e,f   Acchiardo, Sergio R ^a,b,c,d,e,f   Rodriguez, Hector J ^a,b,c,d,e,f   Norris, Keith C ^a,b,c,d,e,f   Sigala, Jerald F ^a,b,c,d,e,f   Rutkowski, Mark ^a,b,c,d,e,f   Robertson, John A ^a,b,c,d,e,f   Goodman, William G ^a,b,c,d,e,f   Levine, Barton S ^a,b,c,d,e,f   Chesney, Russell W ^a,b,c,d,e,f   Mazess, Richard B ^a,b,c,d,e,f   Kyllo, Darlene M ^a,b,c,d,e,f   Douglas, Laura L ^a,b,c,d,e,f   Bishop, Charles W ^a,b,c,d,e,f   Coburn, Jack W ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f BoneCare International Inc   (United States)

Author keywords

1 hydroxyvitamin D2 (1 D2); Doxercalciferol (1 D2); Hemodialysis (HD); Hypercalcemia; Hyperphosphatemia; Intact parathyroid hormone (iPTH); Intravenous trial; Oral trial; Renal failure; Renal osteodystrophy; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; SECONDARY HYPERPARATHYROIDISM;

EID: 17144459471     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(01)80010-X     Document Type: Article

References (19)

1. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
2. 2) therapy for secondary hyperparathyroidism: Results of a modified, double-blinded, controlled study
3. 2 in suppressing 2° hyperparathyroidism in hemodialysis patients
4. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients
5. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism
6. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism
7. Efficacy and limitations of pulse IV and pulse oral 1,25 vit D therapy in treatment of hyperparathyroidism in patients on long term dialysis
8. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
9. Intravenous versus oral calcitriol therapy in renal osteodystrophy: Results of a prospective, pulsed and dose-comparable study
10. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients
11. "Pulse oral" versus intravenous calcitriol therapy in chronic hemodialysis patients: A prospective and randomized study
12. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients
13. Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration
14. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
15. The spectrum of bone disease in end-stage renal failure - An evolving disorder
16. Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure
17. 2 in mammals
18. 2 detectable in human serum
19. 2 made in the human hepatoma, Hep 3B